Cat. No. 4361

Bosutinib C26H29Cl2N5O3 [380843-75-4]

Price and Availability

For Bosutinib pricing & availability please select your country from the drop down menu:
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Alternative Name: SKI-606

Chemical Name: 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile

Biological Activity

Dual inhibitor of Abl and Src kinases (IC50 = 1.2 nM for Src in an enzymatic assay). Displays antiproliferative activity against chronic myelogenous leukemia (CML) cells and decreases the motility and invasion of breast cancer cell lines. Also exhibits potent antiproliferative activity in anchorage-independent, Src-transformed rat fibroblasts (IC50 = 100 nM). Displays selectivity for Src over non-Src family kinases such as growth factor receptor tyrosine kinases.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Technical Data

Soluble to 100 mM in DMSO and to 25 mM in ethanol
>99 %
Store at +4°C

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet

Vultur et al (2008) SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol.Cancer.Ther. 7 1185. PMID: 18483306.

Golas et al (2005) SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res. 65 5358. PMID: 15958584.

Golas et al (2003) SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 63 375. PMID: 12543790.

Boschelli et al (2001) Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J.Med.Chem. 44 3965. PMID: 11689083.

If you know of a relevant reference for this product please let us know.

Citations are publications that use Tocris products.

Do you know of a great paper that uses Bosutinib from Tocris? If so please let us know.

View Related Products by Target

View Related Products by Product Action

Keywords: Bosutinib, supplier, dual, inhibitors, inhibits, abl, src, kinases, antiproliferative, Tocris Bioscience, Src Kinase Inhibitor products

Quick Order

Find multiple products by catalog number

divider line

Tocris: Licensed Supplier of Bosutinib

Tocris Bosutinib validated

Tocris would like to reassure the research community that the bosutinib supplied by Tocris is authentic, fully-licensed material, supplied and assayed by both Pfizer and Tocris.

divider line

New Products in this Area

PI 3065

Potent and selective PI 3-kinase p110δ inhibitor


Potent and selective PFKFB3 inhibitor

STOCK2S 26016

Lysine deficient protein kinase (WNK) signaling inhibitor

rac-CCT 250863

Potent Nek2 inhibitor


Potent, selective cyclin-dependent kinase inhibitor


Potent PKCβ inhibitor

BMS 265246

Potent cdk1/2 inhibitor

Autocamtide-2-related inhibitory peptide, myristoylated

CaM kinase II inhibitor; enhanced cell permeable derivative of Autocamtide-2-related inhibitory peptide

MP A08

Selective ATP competitive SphK1 and 2 inhibitor; cell permeable


Potent and selective dual Akt1 and 2 inhibitor

VX 680

High affinity and selective Aurora kinase inhibitor

Imatinib mesylate

Potent and selective v-Abl tyrosine kinase inhibitor; also inhibits PDGFR and c-kit

TGX 221

Potent and selective PI 3-kinase β inhibitor

PF 543 hydrochloride

Potent and selective SphK1 inhibitor

Sign-up for new product e-alerts
divider line

Bio-Techne Events

Pharmacology 2016

Pharmacology 2016

December 13 - 15, 2016

London, UK